Investigating the role of specific proteins in the brain related to schizophrenia
Cell type specific analysis of Src kinase-NMDA receptor complexes in schizophrenia
This study is looking at how certain proteins in the brain might work together and affect the development of schizophrenia, with the hope of finding new ways to help treat the condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10989333 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain proteins, particularly Src kinase and NMDA receptors, interact in the brain and how these interactions may contribute to the development of schizophrenia. By analyzing these protein complexes, the study aims to uncover the underlying mechanisms of synaptic dysfunction associated with the illness. The approach includes examining postmortem brain tissue and utilizing specific peptides to modify protein interactions, potentially leading to new therapeutic targets for treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schizophrenia who may benefit from novel therapeutic approaches targeting synaptic dysfunction.
Not a fit: Patients with schizophrenia who do not have specific synaptic dysfunction or those with other comorbid psychiatric conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve symptoms and outcomes for individuals with schizophrenia.
How similar studies have performed: Previous research has shown promising results in targeting synaptic pathways in schizophrenia, indicating that this approach may lead to significant advancements in treatment.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Hahn, Chang-Gyu — Thomas Jefferson University
- Study coordinator: Hahn, Chang-Gyu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.